...are they wrong about this? It feels very much like a "shoot the messenger" response. GS isn't saying this is a good outcome, or even that gene therapy compa

...are they wrong about this? It feels very much like a "shoot the messenger" response. GS isn't saying this is a good outcome, or even that gene therapy companies don't deserve investment. They're just claiming that the existing revenue model for drug companies won't lead to success here. The obvious defense of that claim is "if it's true, saying it isn't a sin". I mean, I'm not sure Goldman is intending to make an argument for public healthcare and state-funded medical R&D, but in practice that's what this is.